Updates are available Correction dated 2024-12-11
Click to view Correction: https://doi.org/10.1245/s10434-024-16679-7
-
Authors
Kim, Ji Yong
Yun, Jae Kwang
Kim, Yong-Hee
Park, Seung-il
Lee, Jeong Hoon
Jung, Hwoon-Yong
Lee, Gin Hyug
Song, Ho June
Kim, Do Hoon
Choi, Kee Don
Ahn, Ji Yong
Kim, Sung-Bae
Cho, Kyung-Ja
Ryu, Jin-Sook
Kim, Jong Hoon
Kang, Jihoon
Park, Sook Ryun
Kim, Hyeong Ryul
- License Information
-
More Information
Article History
Received: 5 February 2024
Accepted: 10 June 2024
First Online: 2 July 2024
Change Date: 11 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1245/s10434-024-16679-7
Disclosure
: Sung-Bae Kim Research funding: Novartis, Sanofi-Aventis, and DongKook Pharm Co. Consultant in advisory boards: Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, Beigene, OBI pharma, and Daiichi-Sankyo. Stocks: Genopeaks and NeogeneTC Sook Ryun Park Research funding: Incyte, ImmuneOncia Therapeutics Inc, Ono Pharma Korea co., Ltd.
